Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

Core Viewpoint - Equillium, Inc. is actively engaging with investors and showcasing its innovative therapeutic developments at the upcoming Leerink Partners 2026 Global Healthcare Conference [1] Group 1: Company Overview - Equillium is a biotechnology innovator focused on developing novel therapies for severe autoimmune and inflammatory disorders [2] - The company's lead therapeutic candidate, EQ504, is a potent and selective aryl hydrocarbon receptor (AhR) modulator designed to have a multi-modal, non-immunosuppressive mechanism of action [2] - EQ504 has potential applications for targeted local delivery in treating ulcerative colitis and other gastrointestinal diseases, as well as inhaled formulations for inflammatory lung diseases [2] Group 2: Investor Engagement - Management from Equillium will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026, at 10:40 am ET [1] - The management team will also be available for meetings with registered investors attending the conference [1]